MediLink Therapeutics (Suzhou) Co., Ltd.
22
17
19
0
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
0.0%
0 terminated/withdrawn out of 22 trials
23%
5 trials in Phase 3/4
0%
0 of 0 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (22)
A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)
Role: collaborator
A Study of YL201 in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors
Role: lead
A Study of YL201 Versus Investigator's Choice of Chemotherapy in Participants With Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Failure of First-Line Therapy
Role: lead
A Study YL201 in Patients With Selected Advanced Solid Tumors
Role: lead
YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast Cancer
Role: lead
A Study of YL202 in Patients With Advanced Solid Tumors
Role: lead
Pivotal Study to Evaluate YL202 Versus Docetaxel in Patients With Locally Advanced or Metastatic EGFR Sensitive Mutation Non-Squamous Non-Small Cell Lung Cancer
Role: lead
A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors
Role: lead
A Phase I Study to Evaluate the Safety,Tolerability, Pharmacokinetics, and Efficacy of YL211 in Patients With Advanced Solid Tumors
Role: lead
A Study of YL242 in Subjects With Advanced Solid Tumors
Role: lead
A Clinical Study of YL205 in Patients With Advanced Solid Tumors
Role: lead
A Study of YL201 in Combination With Toripalimab and With or Without Cisplatin in Nasopharyngeal Carcinoma.
Role: lead
A Study of YL202 in Selected Patients With Advanced Solid Tumors
Role: lead
A Study of YL201 and Ivonescimab (AK112) in Advanced Solid Tumors
Role: lead
A Study of YL201 in Patients With Advanced Solid Tumors
Role: lead
A Study of YL202 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors
Role: lead
A Study of YL202 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer and Breast Cancer
Role: lead
A Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Patients With mCRPC
Role: lead
A Phase 1 Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Advanced Solid Tumors
Role: lead
A Phase III Study of YL201 in Relapsed Small Cell Lung Cancer
Role: lead